This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Lee D. Kaufman, MD; Gerald J. Gleich, MD

Arch Dermatol. 1997;133(2):225-227.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE SPECTRUM of disorders characterized by peripheral blood and/or tissue eosinophilia is diverse and heterogeneous. The relative paucity of these diseases has limited the ability to better define clinical subsets, origin, mechanisms of tissue injury, and the development of pathogenically determined therapeutic intervention. Nevertheless, clinical and laboratory data emerging over the past several years have provided important evidence that these illnesses are mediated by cytokines specific to the production, migration, and activation of the eosinophil.

The currently recognized systemic eosinophilic syndromes (unrelated to infectious and neoplastic disease) are distinguished from each other by their clinical and pathological manifestations. Target organ involvement may be localized and benign or generalized, associated with systemic manifestations, and potentially fatal. Diffuse fasciitis with eosinophilia (DFE) (eosinophilic fasciitis or Schulman syndrome) is a sclerodermalike condition characterized by inflammation and fibrous thickening of the subcutaneous fascia.¹ Although involvement is generally limited to the skin, more widespread features . . . [Full Text PDF of this Article]

Author Affiliations
Division of Rheumatology HSC-T16-040 State University of New York at Stony Brook Stony Brook, NY 11794-8161; Rochester, Minn

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?